A Pilot Study of Neoadjuvant Chemotherapy for Locally Advanced Non-small Cell Lung Cancer.

概要

論文の詳細を見る
Neoadjuvant chemotherapy was performed in cases of locally advanced non-small cell lung cancer with CDDP 100-120mg/m2, VDS 3mg/m2, MMC 8mg/m2, (Group A 21 cases) or CDDP 80mg/m2, VDS 3mg/m2 (Group B 19 cases). Resectability and curability after the chemotherapy were about 80% in both group. There were no patients who did not undergo to surgery because of drug toxicity. The clinical response rate for primary tumors was 52% in Group A and 31% in Group B. Only one case had a complete response in each group. The histological response was less effective than the clinical response and no definite correlation was found between the clinical response and the pathological findings. The overall 1-year and 2-year survival rates were 72% and 58%, respectively. Better survival was found among the patients in Group A, both in the clinically and the pathologically good response group. The most common site of treatment failure was distant metastases. These results seem to indicate that neoadjuvant chemotherapy is effective for treating micrometastases.
特定非営利活動法人日本肺癌学会の論文